

genesight

The GeneSight® test provides information about your patient that may help you avoid multiple medication trials.

The GeneSight Psychotropic test is a pharmacogenomic test that analyzes clinically important genetic variations which may impact how your patient metabolizes and responds to certain medications used to treat mental health conditions. The test is a powerful tool to augment your knowledge, experience and passion for your patients.

Tens of thousands of clinicians have ordered the GeneSight test for



clinical studies published in peer-reviewed journals support the GeneSight test's effectiveness.



GeneSight Psychotropic is the only psychiatric pharmacogenomic test backed by such extensive research

In a post-hoc analysis of data from the GUIDED study, the GeneSight Psychotropic test was found to significantly improve clinical outcomes in patients taking medications with gene-drug interactions compared to treatment as usual.¹

- Remission
- ✓ Response
- ✓ Symptom Improvement




For more information on GeneSight studies, visit **GeneSight.com/clinical-studies**

A Comprehensive Report, Personalized for your Patient.

The GeneSight® Psychotropic report provides information about which medications may require dose adjustments, be less likely to work, or have an increased risk of side effects based on your patient's genetic information.



The clinical considerations state rationale for a medication's classification and offer treatment adjustments if a clinician desires to use that medication.



This chart shows which pharmacokinetic pathways each drug uses and whether that pathway is compromised.



Additional genotype/phenotype information for each gene tested and more gene-drug interaction information are also in the report.

Cost shouldn't be a barrier to the GeneSight® test.

We will bill your patient's insurance for the cost of the GeneSight test:

- Medicare (Part B) Covered Tests \$0 out of pocket cost for your patient
- Medicare Advantage Covered Tests your patient may be expected to cover a portion of the cost (typically \$330 or less) and the GeneSight Promise applies
- Medicaid typically, your patient will have a \$0 out of pocket cost
- Commercial or Other Insurance plans vary, but your patient may be expected to cover a portion of the cost (typically \$330 or less) and the GeneSight Promise applies

If your patient doesn't have insurance, please contact our Customer Service team to find out how we can help.

We also offer a payment plan and a financial assistance program to help patients with their out of pocket cost. Learn more about these programs at **GeneSight.com/cost**

The GeneSight Promise

We do our best to make the GeneSight test affordable for your patients. We promise that if your patient's cost could be more than \$330, we will call them before we process their test.

Over

95% of patients pay

\$330 or less

Who Can Benefit from the GeneSight test?

Fewer than 50% of patients with depression respond to their first prescribed medication and with each failed medication trial, their treatment intolerance increases.²

Consider offering the GeneSight test to:



- New patients with a previous medication failure
- Patients who are experiencing lower than desired medication response
- Patients who are currently experiencing unwanted side effects
- Elderly patients and patients with liver damage

The GeneSight test delivers genetic insights that may inform your treatment plan and potentially shorten your patients' road to recovery.



The GeneSight Psychotropic test can provide information that your patients can't.

To order the GeneSight test or request additional information, contact your sales representative or email isrteam@genesight.com

Customer Service 866.757.9204 info@genesight.com Medical Information 855.891.9415 medinfo@genesight.com

Visit **GeneSight.com** to learn more.

Not all patients who receive the GeneSight test will have improved outcomes. The GeneSight test is intended to supplement a clinician's comprehensive medical assessment.

^{1.} Thase ME, et al. 2019 J Clin Psychiatry

^{2.} Rush AJ, et al. 2006 Am J Psychiatry

^{© 2021} Myriad Neuroscience and GeneSight are registered trademarks of Assurex Health, Inc. | All Rights Reserved